{"id":17415,"date":"2025-02-01T22:19:42","date_gmt":"2025-02-01T21:19:42","guid":{"rendered":"https:\/\/francelyme.fr\/site\/?p=17415"},"modified":"2025-02-02T22:25:19","modified_gmt":"2025-02-02T21:25:19","slug":"les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir","status":"publish","type":"post","link":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/","title":{"rendered":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0?"},"content":{"rendered":"<div class=\"like-button\" style=\"float: right; clear: both; text-align: right; width = 100%;\">\n<!-- Facebook Like Button Vivacity Infotech BEGIN -->\n<div class=\"fb-like\" data-href=\"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/\" data-layout=\"box_count\" data-action=\"like\" data-show-faces=\"false\" data-size=\"large\" data-width=\"450\" data-share=\"1\" ><\/div><\/div>\n<!-- Facebook Like Button Vivacity Infotech END -->\n<div id=\"fb-root\"><\/div>\n\n<p>Vous avez peut-\u00eatre entendu parler de cette piste de traitement, qui progresse ces derni\u00e8res ann\u00e9es&nbsp;: la th\u00e9rapie par oligonucl\u00e9otides de soutien (SOT). Les oligonucl\u00e9otides sont des fragments d\u2019ADN ou d\u2019ARN.<\/p>\n\n\n\n<p>Il s\u2019agit d\u2019une approche innovante utilis\u00e9e pour traiter des cancers et des infections chroniques telles que la forme longue de la maladie de Lyme, et des virus, comme le virus d\u2019Epstein-Barr (EBV), le virus de l\u2019herp\u00e8s (HSV) et bien d\u2019autres.<\/p>\n\n\n\n<p>Le principe de cette th\u00e9rapie consiste \u00e0 cr\u00e9er de courts segments d\u2019ADN ou d\u2019ARN qui se lient sp\u00e9cifiquement \u00e0 une s\u00e9quence g\u00e9n\u00e9tique du pathog\u00e8ne. Cette liaison bloque ainsi la r\u00e9plication du pathog\u00e8ne et favorise son \u00e9limination.&nbsp;<\/p>\n\n\n\n<p>Le processus de traitement comporte trois \u00e9tapes.<\/p>\n\n\n\n<p>Un \u00e9chantillon de sang du patient est pr\u00e9lev\u00e9 pour d\u00e9tecter et identifier le pathog\u00e8ne cibl\u00e9. Ensuite, le laboratoire identifie la s\u00e9quence g\u00e9n\u00e9tique sp\u00e9cifique du pathog\u00e8ne et con\u00e7oit un oligonucl\u00e9otide compl\u00e9mentaire qui agira comme une \u201ccl\u00e9\u201d pour bloquer la fonction vitale du pathog\u00e8ne. Cette cl\u00e9 est unique, elle est sp\u00e9cifiquement cibl\u00e9e pour un pathog\u00e8ne bien identifi\u00e9, trouv\u00e9 dans le sang du patient.<\/p>\n\n\n\n<p>Enfin, l\u2019oligonucl\u00e9otide est administr\u00e9 par voie intraveineuse. Une fois dans l\u2019organisme, il circule et p\u00e9n\u00e8tre les cellules infect\u00e9es, inhibant la r\u00e9plication du pathog\u00e8ne pendant plusieurs mois.&nbsp;<\/p>\n\n\n\n<p>Parmi les applications cliniques, figurent en premier lieu les cancers bien s\u00fbr, mais aussi la maladie de Lyme, en ciblant Borrelia burgdorferi, avec une efficacit\u00e9 qui a fait l\u2019objet d\u2019une publication en novembre 2022. Les infections virales chroniques par EBV, HSV, CMV figurent \u00e9galement parmi les applications en cours de d\u00e9veloppement.<\/p>\n\n\n\n<p>Cette th\u00e9rapie comporte deux avantages. Tout d\u2019abord, par sa conception, le SOT est ne s\u2019attaque qu\u2019au pathog\u00e8ne sp\u00e9cifiquement identifi\u00e9 et n\u2019a aucun effet sur les autres microorganismes, ni sur les cellules saines (dans le cas du cancer). Et sa dur\u00e9e d\u2019action est prolong\u00e9e, une seule administration peut offrir une protection contre le pathog\u00e8ne pendant plusieurs mois, voire d\u00e9finitivement.<\/p>\n\n\n\n<p>Les effets secondaires potentiels que peuvent ressentir certains patients sont des sympt\u00f4mes transitoires tels que maux de t\u00eate, courbatures ou fatigue apr\u00e8s l\u2019administration, qui disparaissent g\u00e9n\u00e9ralement dans les 24 ou 48h, mais qui peuvent durer jusqu\u2019\u00e0 une semaine.<\/p>\n\n\n\n<p>Bien que prometteuse, cette th\u00e9rapie SOT est encore en phase d\u2019\u00e9valuation, notamment aux Etats-Unis, sur plusieurs pathologies dont Lyme. M\u00eame si certaines cliniques la pratiquent d\u00e9j\u00e0 aux USA, des recherches compl\u00e9mentaires sont absolument n\u00e9cessaires pour d\u00e9terminer son efficacit\u00e9 \u00e0 long terme et sa s\u00e9curit\u00e9.<\/p>\n\n\n\n<p><em>Pour en savoir plus&nbsp;:<\/em> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9680246\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9680246<\/a><\/p>\n<div class=\"like-button\" style=\"float: right; clear: both; text-align: right; width = 100%;\">\n<!-- Facebook Like Button Vivacity Infotech BEGIN -->\n<div class=\"fb-like\" data-href=\"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/\" data-layout=\"box_count\" data-action=\"like\" data-show-faces=\"false\" data-size=\"large\" data-width=\"450\" data-share=\"1\" ><\/div><\/div>\n<!-- Facebook Like Button Vivacity Infotech END -->\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":17,"featured_media":17439,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[287],"tags":[],"class_list":["post-17415","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme\" \/>\n<meta property=\"og:url\" content=\"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/\" \/>\n<meta property=\"og:site_name\" content=\"Association France Lyme\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/france.lyme\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-01T21:19:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T21:25:19+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminntlyme\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@francelyme\" \/>\n<meta name=\"twitter:site\" content=\"@francelyme\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminntlyme\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/\"},\"author\":{\"name\":\"adminntlyme\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#\\\/schema\\\/person\\\/f7bd0eb75be49e4795c4ea0b3767e039\"},\"headline\":\"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0?\",\"datePublished\":\"2025-02-01T21:19:42+00:00\",\"dateModified\":\"2025-02-02T21:25:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/\"},\"wordCount\":491,\"publisher\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/Supportive-Oligonucleotide-Therapy-.jpg\",\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/\",\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/\",\"name\":\"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/Supportive-Oligonucleotide-Therapy-.jpg\",\"datePublished\":\"2025-02-01T21:19:42+00:00\",\"dateModified\":\"2025-02-02T21:25:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#primaryimage\",\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/Supportive-Oligonucleotide-Therapy-.jpg\",\"contentUrl\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/Supportive-Oligonucleotide-Therapy-.jpg\",\"width\":1024,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#website\",\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/\",\"name\":\"Association France Lyme\",\"description\":\"Association de lutte contre les maladies vectorielles \u00e0 tiques\",\"publisher\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#organization\",\"name\":\"France Lyme\",\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/francelyme-site.gif\",\"contentUrl\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/francelyme-site.gif\",\"width\":180,\"height\":180,\"caption\":\"France Lyme\"},\"image\":{\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/france.lyme\",\"https:\\\/\\\/x.com\\\/francelyme\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClMCGl3dvkz0iAgXFR1NH1A\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/#\\\/schema\\\/person\\\/f7bd0eb75be49e4795c4ea0b3767e039\",\"name\":\"adminntlyme\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g\",\"caption\":\"adminntlyme\"},\"url\":\"https:\\\/\\\/francelyme.fr\\\/site\\\/author\\\/adminntlyme\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/","og_locale":"fr_FR","og_type":"article","og_title":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme","og_url":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/","og_site_name":"Association France Lyme","article_publisher":"https:\/\/www.facebook.com\/france.lyme","article_published_time":"2025-02-01T21:19:42+00:00","article_modified_time":"2025-02-02T21:25:19+00:00","og_image":[{"width":1024,"height":1024,"url":"http:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg","type":"image\/jpeg"}],"author":"adminntlyme","twitter_card":"summary_large_image","twitter_creator":"@francelyme","twitter_site":"@francelyme","twitter_misc":{"\u00c9crit par":"adminntlyme","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#article","isPartOf":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/"},"author":{"name":"adminntlyme","@id":"https:\/\/francelyme.fr\/site\/#\/schema\/person\/f7bd0eb75be49e4795c4ea0b3767e039"},"headline":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0?","datePublished":"2025-02-01T21:19:42+00:00","dateModified":"2025-02-02T21:25:19+00:00","mainEntityOfPage":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/"},"wordCount":491,"publisher":{"@id":"https:\/\/francelyme.fr\/site\/#organization"},"image":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#primaryimage"},"thumbnailUrl":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg","articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/","url":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/","name":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0? - Association France Lyme","isPartOf":{"@id":"https:\/\/francelyme.fr\/site\/#website"},"primaryImageOfPage":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#primaryimage"},"image":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#primaryimage"},"thumbnailUrl":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg","datePublished":"2025-02-01T21:19:42+00:00","dateModified":"2025-02-02T21:25:19+00:00","breadcrumb":{"@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#primaryimage","url":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg","contentUrl":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2025\/02\/Supportive-Oligonucleotide-Therapy-.jpg","width":1024,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/francelyme.fr\/site\/les-oligonucleotides-de-soutien-sot-un-traitement-innovant-a-venir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/francelyme.fr\/site\/"},{"@type":"ListItem","position":2,"name":"Les Oligonucl\u00e9otides de Soutien (SOT)\u00a0: un traitement innovant\u00a0\u00e0 venir\u00a0?"}]},{"@type":"WebSite","@id":"https:\/\/francelyme.fr\/site\/#website","url":"https:\/\/francelyme.fr\/site\/","name":"Association France Lyme","description":"Association de lutte contre les maladies vectorielles \u00e0 tiques","publisher":{"@id":"https:\/\/francelyme.fr\/site\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/francelyme.fr\/site\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/francelyme.fr\/site\/#organization","name":"France Lyme","url":"https:\/\/francelyme.fr\/site\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/francelyme.fr\/site\/#\/schema\/logo\/image\/","url":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2019\/05\/francelyme-site.gif","contentUrl":"https:\/\/francelyme.fr\/site\/wp-content\/uploads\/2019\/05\/francelyme-site.gif","width":180,"height":180,"caption":"France Lyme"},"image":{"@id":"https:\/\/francelyme.fr\/site\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/france.lyme","https:\/\/x.com\/francelyme","https:\/\/www.youtube.com\/channel\/UClMCGl3dvkz0iAgXFR1NH1A"]},{"@type":"Person","@id":"https:\/\/francelyme.fr\/site\/#\/schema\/person\/f7bd0eb75be49e4795c4ea0b3767e039","name":"adminntlyme","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9ab07a36659baa27b55dfef2a5432041c212015f8eb8a8d25b934c17a03cb54?s=96&d=mm&r=g","caption":"adminntlyme"},"url":"https:\/\/francelyme.fr\/site\/author\/adminntlyme\/"}]}},"_links":{"self":[{"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/posts\/17415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/comments?post=17415"}],"version-history":[{"count":2,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/posts\/17415\/revisions"}],"predecessor-version":[{"id":17440,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/posts\/17415\/revisions\/17440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/media\/17439"}],"wp:attachment":[{"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/media?parent=17415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/categories?post=17415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/francelyme.fr\/site\/wp-json\/wp\/v2\/tags?post=17415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}